new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Regeneron Pharmaceuticals Inc patents


      
Recent patent applications related to Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals Inc-related inventors




Count Application # Date Regeneron Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
12015023123608/20/15 Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
22015023254508/20/15 Human antibodies to human delta like ligand 4
32015020862207/30/15 Genetically modified non-human animals and methods of use thereof
42015021077607/30/15 Adam6 mice
52015020158907/23/15 Adam6 mice
62015020357907/23/15 Human antibodies to pd-1
72015020358007/23/15 Human antibodies to pd-l1
82015020359107/23/15 Mutivalent antigen-binding proteins
92015019601507/16/15 Mice that make heavy chain antibodies
102015019755307/16/15 Mice that make heavy chain antibodies
112015019755407/16/15 Mice that make heavy chain antibodies
122015019755507/16/15 Mice that make heavy chain antibodies
132015019755607/16/15 Mice that make heavy chain antibodies
142015019755707/16/15 Mice that make heavy chain antibodies
152015019756407/16/15 Anti-angptl3 antibodies and uses thereof
162015019757807/16/15 Anti-tie2 antibodies and uses thereof
172015019153407/09/15 Human antibodies to human delta like ligand 4
182015017333106/25/15 Human lambda light chain mice
192015017333206/25/15 Human lambda light chain mice
202015017567606/25/15 Fusion polypeptides capable of activating receptors
212015017568806/25/15 Production cell line enhancers
222015017600206/25/15 Human lambda light chain mice
232015016559806/18/15 Devices and methods for facilitating treatment of electrospray columns
242015016664706/18/15 Antikine antibodies that bind to multiple cc chemokines
252015016021506/11/15 Isolating cells expressing secreted proteins
262015015217706/04/15 High affinity human antibodies to human angiopoietin-2
272015015219106/04/15 Dosing regimens for use with pcsk9 inhibitors
282015014734205/28/15 Methods for treating cancer by administering an anti-ang-2 antibody
292015014000205/21/15 Use of a pcsk9 inhibitor to treat hyperlipidemia
302015014355805/21/15 Non-human animals having a humanized b-cell activating factor gene
312015014355905/21/15 Non-human animals having a humanized a proliferation-inducing ligand gene
322015014356105/21/15 Non-human animals having a humanized b-cell activating factor gene
332015014356205/21/15 Non-human animals having a humanized a proliferation-inducing ligand gene
342015011955604/30/15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
352015011075404/23/15 High resolution allele identification
362015011080104/23/15 Human antibodies to gfr alpha 3 and methods of use thereof
372015010573504/16/15 Syringe pistons, systems and methods
382015010696104/16/15 Humanized il-15 animals
392015009929604/09/15 Promoter-regulated differentiation-dependent self-deleting cassette
402015010003004/09/15 Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
412015008967803/26/15 Non-human animals having a humanized signal-regulatory protein gene
422015008967903/26/15 Non-human animals having a humanized signal-regulatory protein gene
432015008968003/26/15 Human lambda light chain mice
442015007908703/19/15 Vegf antagonist formulations
452015008246903/19/15 Humanized il-7 rodents
462015006418903/05/15 Method of treating cancer with dll4 antagonist and chemotherapeutic agent
472015006790103/05/15 Production of fertile xy female animals from xy es cells
482015005622102/26/15 Anti-prlr antibodies and uses thereof
492015005622202/26/15 Anti-prlr antibodies and uses thereof
502015005900902/26/15 Methods for making fully human bispecific antibodies using a common light chain
512015004706102/12/15 Humanized m-csf mice
522015004706202/12/15 Lincrna-deficient non-human animals
532015003733902/05/15 Anti-activin a antibodies and uses thereof
542015004025302/05/15 Genetically modified major histocompatibility complex mice
552015002441201/22/15 Humanized fcgammar mice
562015001717601/15/15 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
572015001718201/15/15 Methods for treating nasal polyposis by administering an il-4r antagonist
582015002022401/15/15 Non-human animals with modified immunoglobulin heavy chain sequences
592015001056801/08/15 Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
602015001302201/08/15 Humanized il-6 and il-6 receptor
612015001302301/08/15 Humanized il-6 and il-6 receptor
622014035637012/04/14 Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
632014035637112/04/14 Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
642014035637212/04/14 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
652014033134011/06/14 Methods and compositions for generating a mouse
662014032221510/30/14 Methods of inhibiting tumor growth by antagonizing il-6 receptor
672014031524910/23/14 Inducible eukaryotic expression system
682014028987609/25/14 Mice that make heavy chain antibodies
692014027164209/18/14 Il-33 antagonists and uses thereof
702014027165309/18/14 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
712014027165809/18/14 Anti-il-33 antibodies and uses thereof
722014027168109/18/14 High affinity human antibodies to human il-4 receptor
732014027309509/18/14 Serum-free cell culture medium
742014027548909/18/14 Apelin fusion proteins and uses thereof
752014028315809/18/14 Rodents with conditional acvr1 mutant alleles
762014025539009/11/14 Method of treating rheumatoid arthritis with an anti-il-6r antibody
772014025541909/11/14 Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
782014025542909/11/14 Methods of treating autoimmune diseases with dll4 antagonists
792014025599509/11/14 High affinity antibodies to human il-6 receptor
802014024866409/04/14 Readily isolated bispecific antibodies with native immunoglobulin format
812014024350408/28/14 Antibodies comprising chimeric constant domains
822014024546608/28/14 Humanized t cell co-receptor mice
832014024546708/28/14 Genetically modified major histocompatibility complex mice
842014024546808/28/14 Non-human animals with modified immunoglobulin heavy chain sequences
852014022002308/07/14 Method of treating osteoarthritis with an antibody to ngf
862014021377307/31/14 Adam6 mice
872014019655007/17/14 Systems and devices for sample handling
882014019976107/17/14 Promoter-regulated differentiation-dependent self-deleting cassette
892014019340207/10/14 Anti-pdgfr-beta antibodies and uses thereof
902014019459707/10/14 Modified chimeric polypeptides with improved pharmacokinetic properties
912014018990007/03/14 Mirna-regulated differentiation-dependent self-deleting cassette
922014017887906/26/14 Compositions and methods for modifying cells
932014017990306/26/14 High affinity human antibodies to human protease-activated receptor 2
942014015470106/05/14 Humanized fc gamma r mice
952014015568906/05/14 Methods of modifying genes in eukaryotic cells
962014015744506/05/14 Low affinity fcgr deficient mice
972014013797805/22/14 System and methods for use in dispensing biopharmaceutical materials
982014013416905/15/14 Methods of treating ovarian cancer with dll4 antagonists
992014013418905/15/14 Anti-prokineticin receptor (prokr) antibodies and uses thereof
1002014013471905/15/14 Recombinant cell surface capture proteins
1012014013727505/15/14 Hybrid light chain mice
1022014013019305/08/14 Mice that make vl binding proteins
1032014013019405/08/14 Mice that make vl binding proteins
1042014012010905/01/14 Human antibodies to human tnf-like ligand 1a (tl1a)
1052014011293004/24/14 Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1062014009931204/10/14 Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
1072014008829503/27/14 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
1082014008276003/20/14 Non-human animals expressing ph-sensitive immunoglobulin sequences
1092014007256303/13/14 Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
1102014007258303/13/14 Methods for treating atopic dermatitis by administering an il-4r antagonist
1112014007297903/13/14 Isolating cells expressing secreted proteins
1122014007298003/13/14 Isolating cells expressing secreted proteins
1132014007301003/13/14 Methods of modifying eukaryotic cells
1142014007558603/13/14 Parental cell lines for making cassette-free f1 progeny
1152014005690302/27/14 Human antibodies to gfr alpha 3 and methods of use thereof
1162014005690702/27/14 Anti-asic1 antibodies and uses thereof
1172014004473002/13/14 Anti-pcsk9 antibodies with ph-dependent binding characteristics
1182014004106802/06/14 Methods of modifying eukaryotic cells
1192014003333601/30/14 Methods of modifying eukaryotic cells
1202014003333701/30/14 Methods of modifying eukaryotic cells
1212014002363701/23/14 Methods of modifying eukaryotic cells
1222014001722801/16/14 Humanized light chain mice
1232014001722901/16/14 Methods of modifying eukaryotic cells
1242014001723801/16/14 Methods of modifying eukaryotic cells
1252014001769501/16/14 Isolating cells expressing secreted proteins
1262014001778101/16/14 Methods of modifying eukaryotic cells
1272014001778201/16/14 Methods for modifying eukaryotic cells
1282014001852201/16/14 Methods of modifying eukaryotic cells
1292014002012401/16/14 Methods of modifying eukaryotic cells
1302014002012501/16/14 Methods of modifying eukaryotic cells
1312014001345601/09/14 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1322014001345701/09/14 Methods of modifying eukaryotic cells
1332013034453812/26/13 Human antibodies to the glucagon receptor
1342013034010412/19/13 Humanized il-7 rodents
1352013033305712/12/13 Humanized non-human animals with restricted immunoglobulin heavy chain loci
1362013032326012/05/13 Stabilized formulations containing anti-dll4 antibodies
1372013032326112/05/13 Purified antibody composition
1382013032378812/05/13 Production cell line enhancers
1392013032379012/05/13 Human lambda light chain mice
1402013032379112/05/13 Restricted immunoglobulin heavy chain mice
1412013032664712/05/13 Human lambda light chain mice
1422013030967011/21/13 Nuclease-mediated targeting with large targeting vectors
1432013031212811/21/13 Promoter-regulated differentiation-dependent self-deleting cassette
1442013031212911/21/13 Promoter-regulated differentiation-dependent self-deleting cassette
1452013029509711/07/13 Human antibodies to fel d1 and methods of use thereof
1462013028075810/24/13 Fusion polypeptides capable of activating receptors
1472013027307010/17/13 Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
1482013026657410/10/13 Human antibodies to human angiopoietin-like protein 4
1492013025987610/03/13 Anti-hla-b*27 antibodies and uses thereof
1502013025988110/03/13 Fusion polypeptides capable of activating receptors
1512013026105610/03/13 Vegf antagonist formulations
1522013025172809/26/13 Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
1532013025491109/26/13 Adam6 mice
1542013024377509/19/13 Multispecific antigen-binding molecules and uses thereof
1552013024378409/19/13 Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1562013024723409/19/13 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1572013024723509/19/13 Mice that produce antigen-binding proteins with ph-dependent binding characteristics
1582013024723609/19/13 Non-human animals expressing ph-sensitive immunoglobulin sequences
1592013023053109/05/13 Human antibodies to clostridium difficile toxins
1602013023053309/05/13 Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
1612013021654708/22/13 Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1622013020949208/15/13 Anti-tie2 antibodies and uses thereof
1632013021013708/15/13 Methods of modifying eukaryotic cells
1642013021271908/15/13 Humanized rodents that express heavy chain containing vl domains
1652013019587808/01/13 Anti-asic1 antibodies and uses thereof
1662013019887908/01/13 Humanized universal light chain mice
1672013019888008/01/13 Mice expressing a limited immunoglobulin light chain repertoire
1682013018679707/25/13 Stabilized formulations containing anti-ang2 antibodies
1692013018927707/25/13 Stabilized formulations containing anti-pcsk9 antibodies
1702013018420507/18/13 Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1712013018581907/18/13 Genetically modified major histocompatibility complex animals
1722013018582007/18/13 Genetically modified major histocompatibility complex animals
1732013018582107/18/13 Common light chain mouse
1742013017114907/04/13 Anti-angptl3 antibodies and uses thereof
1752013016478606/27/13 Fucosylation-deficient cells
1762013015731306/20/13 High affinity antibodies to human il-6 receptor
1772013016015306/20/13 Humanized light chain mice
1782013014974406/13/13 Methods for producing a fusion protein capable of binding vegf
1792013013710105/30/13 Methods of modifying eukaryotic cells
1802013012972205/23/13 Methods for treating cancer by administering an anti-ang-2 antibody
1812013012983005/23/13 Polymer protein microparticles
1822013013037205/23/13 Enhanced expression and stability regions
1832013013038805/23/13 Methods of modifying eurakyotic cells
1842013012200305/16/13 Methods of inhibiting tumor growth by antagonizing il-6 receptor
1852013012200705/16/13 Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1862013011787305/09/13 Humanized il-6 and il-6 receptor
1872013010905305/02/13 Genetically modified t cell receptor mice
1882013011161605/02/13 Genetically modified major histocompatibility complex mice
1892013011161705/02/13 Genetically modified major histocompatibility complex mice
1902013009556504/18/13 Mirna-regulated differentiation-dependent self-deleting cassette
1912013009628704/18/13 Restricted immunoglobulin heavy chain mice
1922013008429704/04/13 Anti-erbb3 antibodies and uses thereof
1932013008463504/04/13 Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1942013008526604/04/13 Anti-pcsk9 antibodies with ph-dependent binding characteristics
1952013007867503/28/13 High affinity human antibodies to human il-4 receptor
1962013006483403/14/13 Methods for treating hypercholesterolemia using antibodies to pcsk9
1972013004549202/21/13 Methods for making fully human bispecific antibodies using a common light chain
1982013003490202/07/13 Fusion polypeptides capable of activating receptors
1992013002889201/31/13 Method of treating osteoarthritis with an antibody to ngf
2002012032210812/20/12 Adam6 mice
2012012032349712/20/12 Non-hypergeometric overlap probability
2022012025809810/11/12 Method of treating rheumatoid arthritis with an anti-il-6r antibody
2032012026035710/11/12 Low affinity fcgr deficient mice
2042012019589608/02/12 Igf-1 fusion polypeptides and therapeutic uses thereof
2052012018963507/26/12 Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
2062012019230007/26/12 Common light chain mouse
2072012017868307/12/12 Vegf antagonist formulations
2082012016468806/28/12 High affinity human antibodies to human nerve growth factor
2092012013501005/31/12 High affinity human antibodies to human il-4 receptor
2102012012867905/24/12 Human antibodies to the glucagon receptor
2112012011464505/10/12 Use of il-1 antagonists to treat pseudogout
2122012011465405/10/12 Human antibodies to human tnf-like ligand 1a (tl1a)
2132012011466505/10/12 Human antibodies to human rankl
2142012009756504/26/12 Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
2152012010014504/26/12 Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
2162012010103504/26/12 Vegf antagonist formulations
2172012009382404/19/12 Methods for treating pruritus by administering an antibody that specifically binds human par2
2182012009657204/19/12 Mice that make vl binding proteins
2192012008792904/12/12 Vegf antagonist formulations for intravitreal administration
2202012008300004/05/12 Neuropeptide release assay for sodium channels
2212012007679003/29/12 Anti-cd48 antibodies and uses thereof
2222012007086103/22/12 Human lambda light chain mice
2232012007300403/22/12 Hybrid light chain mice
2242012006462103/15/12 Cell culture compositions capable of producing a vegf-binding fusion polypeptide
2252012005207203/01/12 High affinity human antibodies to human il-4 receptor
2262012004544002/23/12 Method of treating rheumatoid arthritis with an anti-il-6r antibody
2272012002140901/26/12 Common light chain mouse
2282012001496801/19/12 Stabilized formulations containing anti-ngf antibodies
2292012000369701/05/12 High affinity antibodies to human il-6 receptor
2302011031834212/29/11 Methods of using il-1 antagonists to treat autoinflammatory disease
2312011031153712/22/11 Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
2322011030796612/15/11 Mice expressing human voltage-gated sodium channels
2332011030796812/15/11 Production of fertile xy animals from xy es cells
2342011029363012/01/11 Antibodies to human gdf8
2352011028337611/17/11 Methods of modifying eukaryotic cells
2362011026918711/03/11 High affinity human antibodies to human il-18 receptor
2372011025614810/20/11 Methods for treating hypercholesterolemia using antibodies to pcsk9
2382011025655610/20/11 Humanized fcgr mice
2392011025658710/20/11 High affinity human antibodies to human nerve growth factor
2402011025760110/20/11 Vegf antagonist formulations for intravitreal administration
2412011025871010/20/11 Methods of modifying eukaryotic cells
2422011019545408/11/11 Common light chain mouse
2432011018917608/04/11 Methods of treating diseases with dll4 antagonists
2442011018920008/04/11 Methods of treating autoimmune diseases with dll4 antagonists
2452011017124107/14/11 Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
2462011016565007/07/11 Fusion polypeptides capable of activating receptors
2472011015901506/30/11 Human antibodies to human angiopoietin-like protein 4
2482011015090506/23/11 Human antibodies to human delta like ligand 4
2492011015451206/23/11 Humanized fc gamma r mice



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE